(Another one is: little to no immune system aggravation as with viral vectors.) There are successful treatments riding on AAV vectors, like Luxturna a successful RP eye disease treatment for LCA. Other AAV like AAV2 are also in a couple of Optogenetic human trials for mixed versions of RP. All of them are probably expensive, until the present small FDA trial safety results permit bulk manufacture. All in a good cause.
PYC Price at posting:
6.6¢ Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)